Pharma | 30 July 2022 | Opinion
Is Industry 4.0 Promising The Moon?
As pharma shifts from generic drugs to personalised medicines, it has become apparent that conventional system...Read more
Healthcare | 30 July 2022 | Opinion
Drones also referred to as unmanned aerial vehicles (UAV), are slowly making their presence felt in the health...Read more
Specials | 30 June 2022 | Opinion
From Hazy to Crystal Clear Picture of Compensation Trends
Compensation is always tricky to determine, both as a professional and for organisations. Across all markets, ...Read more
Medical Diagnostic | 30 June 2022 | Opinion
“Spending on TB control programmes had dropped to 2016 levels in 2020 and remains unchanged”
How is QIAGEN helping to reduce the growing burden of TB in APAC? QIAGEN promotes TB prevention (Test and Tre...Read more
Medical Devices | 28 June 2022 | Opinion
"Asia Pacific is one of the focused areas for Freudenberg Medical"
What will be your latest innovations in the healthcare and pharma industry? Freudenberg is a global t...Read more
Japan | 01 July 2022 | News
Catalent expands primary packaging capabilities in Japan
Catalent has announced the expansion of its primary packaging capabilities at its clinical supply facilit...Read more
North America | 24 June 2022 | News
Merck unveils €59 M CDMO facility for critical cancer therapies
Merck has announced that its Life Science business sector has doubled its high-potent active pharmaceutical in...Read more
Keeping Pace with MUTATING VIRUSES
A surge in the pandemic has forced the pharma industry to deliver a wide-spectrum vaccine to fight mutation-prone SARS-CoV-2, pledging to prevent future outbreaks. WHO states that the most extensive vaccination campaign in history is providing prophylactic results by delivering more than 12 billion doses of the COVID-19 vaccine, protecting 60 per cent of the global population as of June 2022. Now the next-generation COVID-19 vaccines are countering the challenge of enhancing the immune response to tackle the emerging COVID-19 variants. It is therefore imperative to remain vigilant and upgrade vaccine candidates to emerging virus sublineages. In order to gain a competitive position in the market, vaccine manufacturers are investing in advanced platform technologies. Let’s take a closer look at some of these leading vaccines approved in APAC as broad spectrum virucide inhibitors.
For Feedback Email Us: communications@biospectrumasia.com
1 North Bridge Road,
#08-08 High Street Centre,
Singapore 179094
Email : communications@biospectrumasia.com
